The Globe and Mail reports in its Wednesday, May 6, edition that Industrial Alliance Securities analyst Chelsea Stellick believes Microbix Biosystems (32 cents) is "poised to gain global attention as a result of the COVID-19 pandemic where increased testing and the need for quality control will increase the demand for MBX's expertise to develop controls to test for the SARS-CoV-2 virus." The Globe's David Leeder writes in the Eye On Equities column that Ms. Stellick, seeing "ample" upside, began coverage on Microbix with a "speculative buy" rating. Mr. Leeder notes that Ms. Stellick is the lone analyst covering the stock. She set a share target of 50 cents. Ms. Stellick says in a note: "For over 30 years, Microbix has offered an expansive library of royalty-free bacteria, host cells, and viruses to over 100 leading international diagnostic companies for infectious disease testing. The company grows, purifies, and inactivates bacteria and viruses as a key ingredient for immunoassays to establish the presence of human antibodies. MBX is also a global leader in quality assessment and proficiency testing products used in diagnostic laboratories to meet quality objectives and requirements."
© 2020 Canjex Publishing Ltd. All rights reserved.